EU drug regulator records 415 cases of possible rare blood clotting

1 minute read

A medical worker prepares a dose of Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp, Belgium March 18, 2021. REUTERS/Yves Herman/File Photo

Register now for FREE unlimited access to Reuters.com

LONDON, June 17 (Reuters) - The EU drug regulator said on Thursday it has received reports of 415 possible cases of rare blood clotting with a low platelet count in the European Economic Area, out of more than 50 million people who have received AstraZeneca and Johnson & Johnson COVID-19 vaccines.

There have been 10 possible cases among just under 6 million people who received J&J's shot in the EEA, and 405 cases among 45 million who received AstraZeneca's (AZN.L) shot, Georgy Genov, head of pharmacovigilance at the European Medicines Agency said in a briefing.

The condition is known as thrombosis with thrombocytopenia syndrome (TTS).

Register now for FREE unlimited access to Reuters.com
Reporting by Josephine Mason and Matthias Blamont Editing by Peter Graff

Our Standards: The Thomson Reuters Trust Principles.